Also, there was a significant association of decreased FUBP3 expression with increased bone marrow fibrosis which is a central pathological feature in the monitoring of leukaemias, with progressive fibrosis being an indicator of adverse outcomes in CML patients.49 This evidence concerns the gene FUBP3 and chronic myelogenous leukemia, BCR-ABL1 positive.